Table 7 Mean changes in SF-12 physical and mental component summary scores by discontinuation status among patients switched to lurasidone
| Â | Parameter | All patients | Sedating | Non-sedating | |||
|---|---|---|---|---|---|---|---|
Discontinued* | Completed | Discontinued* | Completed | Discontinued* | Completed | ||
(n = 37) | (n = 198) | (n = 18) | (n = 65) | (n = 19) | (n = 133) | ||
Physical component summary | Baseline (SD) | 46.8 (8.8) | 47.2 (10.4) | 48.3 (9.0) | 46.8 (10.7) | 45.3 (8.6) | 47.3 (10.2) |
LOCF (SD) | 46.6 (10.2) | 47.0 (9.8) | 50.6 (7.2) | 46.1 (9.9) | 42.3 (11.6) | 47.4 (9.8) | |
Mean change (SD) | -1.1 (9.6) | -0.1 (8.4) | 1.5 (5.7) | -0.6 (8.5) | -3.9 (12.3) | -0.1 (8.3) | |
p-value** | 0.915 | 0.142 | 0.106 | ||||
Mental component summary | Baseline (SD) | 41.7 (11.4) | 41.3 (11.4) | 39.9 (11.9) | 40.2 (11.7) | 43.3 (11.0) | 41.9 (11.3) |
LOCF (SD) | 42.3 (12.2) | 45.5 (10.9) | 38.8 (14.7) | 45.1 (12.0) | 46.1 (7.5) | 45.8 (10.4) | |
Mean change (SD) | -1.6 (14.6) | 4.3 (11.0) | -3.5 (18.9) | 4.9 (11.9) | 0.5 (8.4) | 4.0 (10.5) | |
p-value** | 0.029 | 0.036 | 0.498 | ||||